a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfullypassedits first GMP inspection by the European Medicines Agency (EMA), with no critical findings. This is one of the largest biosafety testing laboratories globall...
Suzhou, China, April 14, 2020, WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfully passed its first GMP inspection by the Euro
WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leadi... 2024-08-01 15:002848 WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (22...
It was founded in 2019 and is based in Suzhou, China. Samsung BioLogics Samsung BioLogics is a fully integrated contract development and manufacturing organization (CDMO) specializing in the biopharmaceutical sector. The company offers a range of services including the development and manufacturing of ...
WuXi Biologics is a subsidiary of the WuXi AppTec Group with branches in Wuxi, Shanghai and Suzhou. As a platform for innovative companies to realize their dream of developing new drugs, WuXi AppTec is expected to provide world-class integrated biopharma
(Hong Kong, March 22, 2023) – WuXi Biologics (Cayman) Inc. (“WuXi Biologics” or “the Group”, stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions f
Dr. Chris Chen, CEO of WuXi Biologics, commented, “The second EMA certificate is the solid proof of our world-class quality system as well as the technology platforms utilized at our Suzhou facility. However, continuous improvement is the foundation of our organization and thus we will continue...
— In December 2019, WuXi AppTec (Suzhou) Co., Ltd., a subsidiary of the company, acquired 100% equity of Suzhou Kang Lu Biotechnology Co., Ltd. from its original shareholder at a consideration of RMB803.8 million During the Reporting Period, investment in joint ventures and associates ...
Bull or Bear, Seeking Alpha is there Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings. Create Free Account WXIBFWuXi Biologics (Cayman) Inc. Related Analysis 391 followers $2.190.02 (+0.92%)12:22 PM 01/10/25 ...
SHANGHAI, February 27, 2018 — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner MabSpace Bioscienc